default author photo

Matias A. Bustos

Saint John’s Cancer Institute at Providence Saint John’s Health Center

SCHOLARLY PAPERS

2

DOWNLOADS

72

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

The Landscape of Gain and Loss of Function Mutations in Melanoma

Number of pages: 41 Posted: 31 Jul 2025
University of Pennsylvania, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, University of Pennsylvania, University of Pennsylvania - Tara Miller Melanoma Center, University of Pennsylvania - Tara Miller Melanoma Center, University of Pennsylvania, University of Pennsylvania - Division of Hematology/Oncology, University of Pennsylvania, University of Pennsylvania, University of Pennsylvania, University of Pennsylvania, Saint John’s Cancer Institute at Providence Saint John’s Health Center, Saint John’s Cancer Institute at Providence Saint John’s Health Center, Saint John’s Cancer Institute at Providence Saint John’s Health Center, University of Texas at Houston, University of Texas at Houston, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, Oregon Health and Science University - Division of Oncological Sciences, Harvard University - Massachusetts General Hospital, Harvard University - Massachusetts General Hospital, Harvard University - Massachusetts General Hospital, Harvard University - Massachusetts General Hospital, Harvard University - Massachusetts General Hospital, Massachusetts General Hospital and Harvard Medical School - Center for Cancer Immunology, Oregon Health and Science University, Wistar Institute, Wistar Institute and Independent
Downloads 48 (1,097,529)

Abstract:

Loading...

Melanoma, Multi-omics, PDX models, Variant classification, Computational modeling

2.

UBQLN1-Mediated Repression of Homologous Recombination is an Actionable Target for Cancer Therapy

Number of pages: 86 Posted: 01 Apr 2026
Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, University of Cologne, University of Seville, University of Seville, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, University of Cologne, Max Planck Institute for Biology of Ageing, Max Planck Institute for Biology of Ageing, University of Cologne, University of Cologne, Max Planck Institute for Biology of Ageing, Providence Saint John's Health Center (SJHC), University of Duisburg-Essen - University Hospital Essen, Max Planck Institute for Biochemistry, University of Cologne, Max Planck Institute for Biology of Ageing, Max Planck Institute for Metabolism Research, Max Planck Institute for Biology of Ageing, University of Cologne - University Hospital of Cologne, Tel Aviv University, Providence Saint John's Health Center (SJHC), University of Cologne, University of Cologne, University of Cologne, Zeynep Kamil Maternity and Children's Training and Research Hospital, Baylor College of Medicine, Baylor College of Medicine, University of Cologne, Max Planck Institute for Biology of Ageing, University of Seville, Heinrich Heine University Dusseldorf, Heinrich Heine University Dusseldorf, University of Cologne, University of Cologne, Saint John’s Cancer Institute at Providence Saint John’s Health Center, University of Cologne, Heinrich Heine University Dusseldorf, Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen and Max Planck Institute for Biology of Ageing
Downloads 24 (1,436,435)

Abstract:

Loading...

DNA damage, DNA double-strand break repair, Homologous recombination, cancer, targeted cancer therapy, UBQLN1 deficiency syndrome, UBQLN1, RAD51, MRE11, genome instability, syndrome, Ubiquitin, proteasomal degradation, Lung Cancer, PARP, ICB